Zhiyong Ma

Efficacy, safety, and genetic analysis of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small-cell lung cancer: a phase 2b, multicentre, single-arm, open-label study

Yuankai Shi, Xingsheng Hu, Shucai Zhang et al. · The Lancet Respiratory Medicine · 2021 · 115 citations

Genetic Analysis, Egfr T790m, Phase 2B +12

Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations

Huijuan Wang, Ziqi Wang, Guowei Zhang et al. · Cancer Medicine · 2019 · 74 citations · Full text

Transcriptional Control of BubR1 by p53 and Suppression of Centrosome Amplification by BubR1

Tatsuo Oikawa, Masaru Okuda, Zhiyong Ma et al. · Molecular and Cellular Biology · 2005 · 71 citations · Full text

Spindle/chromosome Aberrations, Molecular Biology, Cell Cycle +20

CTONG 1509: Phase III study of bevacizumab with or without erlotinib in untreated Chinese patients with advanced EGFR-mutated NSCLC

Qing Zhou, Yi‐Long Wu, Ying Cheng et al. · Annals of Oncology · 2019 · 55 citations

Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort study

Guowei Zhang, Ruirui Cheng, Huijuan Wang et al. · Cancer Immunology Immunotherapy · 2020 · 51 citations · Full text

Neuro-oncology, Advanced Nsclc, Retrospective Cohort Study +6